Search Results

Aerin Medical Inc. today announced the publication of positive 24-month results from RHINTRAC, a randomized, sham-controlled clinical trial, in the International Forum of Allergy & Rhinology (IFAR).

Aerin Medical Announces Positive Two-year Outcomes from the VATRAC Trial of VivAer .

Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced that Derrick Sung has been appointed chief financial officer of the company.

Aerin Medical Announces Sustained Clinical and Quality-of-Life Improvements Two Years After Chronic Rhinitis Treatment with RhinAer ®.

Aerin Medical Inc. announced that the Centers for Medicare and Medicaid Services assigned payment for a new Category I Current Procedural Terminology code for endoscopic destruction of the posterior nasal nerve using radiofrequency ablation.

Aerin Medical Inc. today announced the publication of positive two-year follow-up data from the AERWAY trial for patients with severe or extreme nasal airway obstruction (NAO) due to nasal valve collapse (NVC).

Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, supports the recent American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) position statement.

Aerin Medical Inc. announced that the American Medical Association Current Procedural Terminology Editorial Panel accepted the application for a new Category I CPT code to report endoscopic destruction of the posterior nasal nerve using radiofrequency ablation.

Aerin Medical Inc. a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, today announced it has recently closed a $60 million equity financing.

Aerin Medical Inc. announced today that the Centers for Medicare and Medicaid Services (CMS) assigned physician and facility payment for a new Category I Current Procedural Terminology (CPT®) code that includes the use of VivAer® to repair nasal valve collapse (NVC) when performed in the office and outpatient surgical settings.